Avalon GloboCare Corp. (AVCO)

NASDAQ: AVCO · IEX Real-Time Price · USD
0.440
-0.030 (-6.40%)
Jun 24, 2022 4:00 PM EDT - Market closed
-6.40%
Market Cap 39.14M
Revenue (ttm) 1.40M
Net Income (ttm) -8.79M
Shares Out 88.96M
EPS (ttm) -0.10
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 110,485
Open 0.470
Previous Close 0.470
Day's Range 0.440 - 0.481
52-Week Range 0.401 - 1.190
Beta 0.81
Analysts n/a
Price Target n/a
Earnings Date May 13, 2022

About AVCO

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical tria... [Read more...]

Industry Health Care Providers & Services
Employees 5
Stock Exchange NASDAQ
Ticker Symbol AVCO
Full Company Profile

Financial Performance

In 2021, AVCO's revenue was $1.39 million, an increase of 0.96% compared to the previous year's $1.38 million. Losses were -$9.09 million, -28.31% less than in 2020.

Financial Statements

News

Avalon GloboCare to Present at the Jefferies 2022 Healthcare Conference

FREEHOLD, N.J., May 25, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of innovative cell-based technologies and therapeutics, announced today that David Jin,...

Avalon GloboCare Adds CAR-NK Cell Therapies To Expand Cellular Immuno-Oncology Platform

Avalon GloboCare Corp (NASDAQ: AVCO) is expanding its cellular immuno-oncology program with the addition of novel Chimeric Antigen Receptor – Natural Killer (CAR-NK) cell therapies. Avalon is leveraging...

Avalon GloboCare Expands its Cellular Immuno-Oncology Platform with the Addition of Novel Chimeric Antigen Receptor-N...

FREEHOLD, N.J., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of cell-based technologies and therapeutics, announced today that the Company is expan...

Avalon GloboCare Provides Year-End Business Update of Selective Scientific and Clinical Programs

Company continues to expand and accelerate its R&D strategies for high-impact translational and clinical programs in the US and Europe

Avalon GloboCare's Chairman Converts Debt into Common Stock at 45% Premium to Market

Avalon's Chairman converts $3.0 million of debt into common stock at $1.25 per share showing continued confidence and support of the business Avalon's Chairman converts $3.0 million of debt into common ...

Avalon GloboCare Advances AI-Enhanced Protein Design Technology for Cellular Therapy Development

FREEHOLD, N.J., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today anno...

Avalon GloboCare Jointly Files US and International Patent Application for Breakthrough S-Layer Coated Emulsome Techn...

FREEHOLD, N.J., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today anno...

Avalon GloboCare's Advanced Filtration Tech Could Help Stop Life-Threatening Cytokine Storm in COVID-19 Patients

Image Provided by Pixabay Cytokine storm has made frequent appearances in the news lately as a life-threatening complication in patients suffering from COVID-19. The condition is an inflammatory syndrom...

Avalon GloboCare and University of Natural Resources and Life Sciences (BOKU) Co-develop Innovative In-Silico Technol...

FREEHOLD, N.J., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today anno...

Avalon GloboCare Aims to Revolutionize Cell Therapy Market with a Faster, Safer CAR-T Treatment

Image Provided by Pexels With a compound annual growth rate (CAGR) of 34.2%, the global CAR-T cell therapy market is projected to hit $15.4 billion by 2028. This hypergrowth is largely driven by the inc...

UPMC and Pitt Develop New Cancer Immunotherapy with Avalon GloboCare

PITTSBURGH, Aug. 04, 2021 (GLOBE NEWSWIRE) -- A new collaboration among UPMC Hillman Cancer Center, the University of Pittsburgh and New Jersey-based biotechnology company Avalon GloboCare Corp. (NASDAQ...

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Avalon GloboCare Corp. - AVCO

NEW YORK, July 16, 2021 /PRNewswire/ --  Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Actio...

Avalon GloboCare Announces its Planned Acquisition Target, SenlangBio, has Initiated First-In-Human Clinical Trial in...

Trial evaluating EphA2-targeted CAR T-cell therapy in recurrent glioblastoma, an urgent and significant unmet medical need with no standard of care treatment option

Avalon GloboCare CEO Provides Letter to Update Shareholders About Acquisition of SenlangBio

Previously Announced Execution of Definitive Agreement to Acquire SenlangBio

INVESTIGATION ALERT: Halper Sadeh LLP Investigates FBNC, AVCO, XEC, CLDR, SBBP; Shareholders are Encouraged to Contac...

NEW YORK, June 15, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: First Bancorp (NASDAQ: FBNC)  concerning potential vio...

Other symbols: FBNC

Avalon Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Merger of Avalon GloboCare Cor...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger of Avalon GloboCare Corp. (NASDAQ: AVCO) and Hebei Senlang Biotechnology Co. Ltd is fa...

Avalon GloboCare Adds Cell Therapy-Based Candidates For Cancer With SenlangBio Acquisition: Highlights

Avalon GloboCare Corp (NASDAQ: AVCO) has agreed to acquire Hebei Senlang Biotechnology, dubbed SenlangBio, a China-based cell therapy company, in an all-stock transaction. In connection with the transac...

Avalon GloboCare Announces Execution of Purchase Agreement for Acquisition of SenlangBio in All Stock Transaction

SenlangBio, a world-class cell therapy company, has developed a robust pipeline which includes 15 autologous and universal (“off-the-shelf”) CAR-T and CAR-γδ T cell therapy candidates targeting hematolo...

Avalon GloboCare to Present at the Noble Capital Markets Investor Forum During the 16th Annual World Stem Cell Summit...

FREEHOLD, N.J., June 11, 2021 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today anno...

Avalon GloboCare To Present Its S-Layer and QTY Code Breakthrough Technology Platforms at The Prestigious Annual Worl...

FREEHOLD, N.J., June 08, 2021 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today anno...

Avalon GloboCare Announces Collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center to Ad...

FREEHOLD, N.J., March 29, 2021 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today ann...

Avalon GloboCare Expands Co-Development Program with MIT to Combat Cancer Metastasis

FREEHOLD, N.J., March 22, 2021 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today ann...

Avalon GloboCare and University of Natural Resources and Life Sciences (BOKU) Expand Partnership and Accelerate Devel...

FREEHOLD, N.J., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO) (Avalon or The Company), a clinical-stage global developer of cell-based technologies and therapeutics, today anno...

Avalon GloboCare and Adial Pharmaceuticals Announce Strategic Collaboration for Global Distribution of COVID-19 Point...

Assure/Fastep® COVID-19 Point-of-Care Antibody Test is the First Test Granted FDA Emergency Use Authorization for Use with Fingerstick Blood Samples Assure/Fastep® COVID-19 Point-of-Care Antibody Test i...

Avalon GloboCare Provides Clinical Updates on Its CAR-T Immuno-Oncology and Allogeneic Mesenchymal Stromal Cell (MSC)...

FREEHOLD, N.J., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a clinical-stage global developer of cell-based technologies and therapeutics, today provided a clinical update o...